References
- Kralovics R, Passamonti F, Buser AS, et al A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779–1790.
- Baxter EJ, Scott LM, Campbell PJ, et al Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054–1061.
- Swerdlow SH, Campo E, Harris NL, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon: IARC; 2008.
- Steensma DP, Dewald GW, Lasho TL, et al The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferative disorders and myelodysplastic syndromes. Blood 2005;106:1207–1209.
- Gattermann N, Billiet J, Kronenwett R, et al High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count >600 × 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007;109:1334–1335.
- Schmitt-Graeff AH, Teo SS, Olschewski M, et al JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2008;93:34–40.
- Malcovati L, Della Porta M, Pietra D, et al Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009;114:3538–3545.
- Ingram W, Lea NC, Cervera J, et al The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006;20:1319–1321.
- Wong KF, Wong WS, Siu LL, Lau TC, Chan NP. JAK2 V617F mutation is associated with 5q− syndrome in Chinese. Leuk Lymphoma 2009;50:1333–1335.
- Cheson B, Greenberg P, Bennett J, et al Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.
- Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leuk Res 2010;34:821–823.